United Therapeutics (UTHR) Form 4 Filings

United Therapeutics Corp. (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options at $117.76 per share on October 28, 2026, acquiring 9,500 common shares. The reported post-exercise option position was 138,410 options. The trust sold 9,500 shares in six transactions at weighted-average prices from $583.5017 to $588.3913 per share, under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported the exercise of 9,500 options held in a family trust at $117.76 per share, acquiring 9,500 common shares on October 27, 2026. Trust-held shares were sold at reported weighted-average prices from $582.6649 to $592.8350 per share.

The exercise and sales were under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. It continues until the earlier of exercise of 1,734,410 options, all expiring March 15, 2027, or December 31, 2026. The reported option balance afterward was 147,910.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options on October 26, 2026, at $117.7600 per share, resulting in 9,500 common shares. The resulting shares were sold through family trusts in eight reported transactions, including a 600-share sale at a weighted-average price of $585.7122 per share and an 806-share sale at $592.9168 per share. The exercise and sales were under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025; the reported option position following the exercise was 157,410.

United Therapeutics' Chairperson & CEO, Martine A. Rothblatt, reported that a family trust in which she shares investment power exercised 9,500 stock options at $117.76 per share on October 23, 2026, and family trusts sold the resulting 9,500 common shares in 11 reported transactions. The sale prices were reported as weighted averages ranging from $577.6774 to $587.9997 per share. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The trust's reported option balance following exercise was 166,910 stock options.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options for 9,500 common shares at an exercise price of $117.76 on October 22, 2026; family trusts sold 9,500 resulting shares that day. Reported per-share prices across the sale entries ranged from $562.9700 to $590.3970.

The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported post-transaction stock-option position was 176,410 options. Separate holdings entries list 40,513 directly held common shares and 166 shares held by her spouse.

United Therapeutics Corp. (UTHR) reported that Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options on October 21, 2026, at $117.76 per share. The resulting 9,500 shares held through family trusts were sold that day. The exercise and sales were made under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, 185,910 stock options were reported as held through a family trust.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options at $117.76 per share on October 20, 2026; the resulting 9,500 common shares were sold in 17 transactions through family trusts. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The report lists 195,410 stock options following the exercise.

United Therapeutics Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options on October 19, 2026, at $117.76 per share and acquired 9,500 common shares; the trust also sold 9,500 shares at reported weighted-average prices ranging from $534.7498 to $556.8750 per share. The exercise and sale were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported post-exercise option position was 204,910 options.

United Therapeutics Corp. Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shared investment power exercised 9,500 stock options at an exercise price of $117.76 per share on October 16, 2026, acquiring 9,500 common shares and selling 9,500 resulting shares in 13 reported sales. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported post-exercise balance was 214,410 stock options.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shares investment power exercised 9,500 stock options on October 15, 2026, at an exercise price of $117.76 per share, then sold the 9,500 resulting common shares in multiple trades. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The trust's reported post-transaction stock-option position was 223,910 options, which expire March 15, 2027.

United Therapeutics Corp. (UTHR) EVP & General Counsel Paul A. Mahon exercised options for 8,300 common shares on October 15, 2026, at an exercise price of $146.03 per share, then sold the 8,300 shares in six transactions at reported weighted-average prices from $541.6421 to $546.5608 per share. The exercise and sales were made under a pre-arranged 10b5-1 plan entered into August 11, 2025. After the exercise, his reported position was 30,940 stock options.

United Therapeutics (UTHR) reported that family trusts in which Chairperson & CEO Martine A. Rothblatt shares investment power exercised 9,500 stock options at an exercise price of $117.7600 per share on October 14, 2026, acquiring 9,500 common shares and selling 9,500 common shares in multiple transactions. Reported sale prices ranged from $526.0700 to $546.0000 per share. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported stock-option position after the transaction was 233,410 shares.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options at an exercise price of $117.76 per share on October 13, 2026, acquiring 9,500 common shares and selling 9,500 shares in ten transactions. Reported weighted-average sale prices ranged from $542.7569 to $551.4900 per share. The exercise and sales were under a pre-arranged 10b5-1 trading plan adopted by Rothblatt on November 7, 2025. The trust held 242,910 stock options following the exercise.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shares investment power exercised 9,500 stock options on October 12, 2026, at a $117.76 exercise price, then sold the resulting 9,500 common shares. The exercise and sales were under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported option position after the exercise was 252,410 options.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported the exercise by a family trust of 9,500 stock options on October 9, 2026, at $117.76 per share, producing 9,500 common shares; the trust sold all 9,500 shares in multiple trades. The exercise and sales were under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. The reported stock-option position following the exercise was 261,910 options.

At United Therapeutics (UTHR), Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shares investment power exercised 9,500 stock options at $117.76 per share on October 8, 2026, acquiring 9,500 common shares. The trust sold 9,500 common shares that day in multiple trades at reported prices ranging from $525.4958 to $541.2300 per share. The exercise and sales were under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported stock-option position afterward was 271,410 shares.

Martine A. Rothblatt, United Therapeutics' Chairperson & CEO, reported that a family trust exercised 9,500 stock options at $117.76 per share on October 7, 2026, acquiring 9,500 common shares and selling 9,500 shares in 14 reported sale entries. The exercise and sales were under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported stock-option position following the exercise was 280,910 shares.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported an exercise of stock options through a family trust for 9,500 common shares on October 6, 2026, at $117.76 per share, followed by sales of 9,500 shares in 17 transactions through family trusts. The sales included 280 shares at a reported weighted-average price of $527.9029 per share and 80 shares at $545.4950 per share. The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

A family trust associated with United Therapeutics Chairperson & CEO Martine A. Rothblatt exercised stock options covering 9,500 common shares on October 5, 2026, at an exercise price of $117.76 per share; family-trust holdings also sold the resulting 9,500 shares. Reported weighted-average sale prices ranged from $536.2579 to $546.6322 per share. The exercise and sales were made under a pre-arranged 10b5-1 trading plan adopted November 7, 2025, set to continue until the earlier of exercise of 1,734,410 stock options, all expiring March 15, 2027, or December 31, 2026.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported the exercise of 9,500 stock options held in a family trust at an exercise price of $117.76 per share and the sale by family trusts of 9,500 resulting common shares on October 2, 2026. One reported sale was 700 shares at a weighted-average price of $542.0614 per share. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025.

The reported stock-option position after the exercise was 309,410. As of October 2, 2026, reported common-stock holdings included 40,513 shares held directly and 166 shares held indirectly by spouse.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported exercising 9,500 stock options held by a family trust on October 1, 2026, at an exercise price of $117.76. The trust acquired 9,500 common shares and sold 9,500 shares in 19 reported transactions, with reported weighted-average prices per transaction ranging from $560.05 to $584.6622 per share. The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The stock-option entry records 318,910 options following the transaction. The footnotes identify the shares as held in family trusts and state that Rothblatt shares investment power over the relevant trust holdings.

United Therapeutics (UTHR) executive vice president and general counsel Paul A. Mahon exercised stock options for 8,300 common shares at a $146.0300 exercise price on October 1, 2026, then sold the resulting 8,300 shares in multiple trades under a pre-arranged 10b5-1 plan. After the exercise, his reported position was 39,240 stock options.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported sales of 1,920 common shares on September 30, 2026, through family trusts in which she shares investment power. The eight reported weighted-average prices ranged from $547.2940 to $554.6997 per share. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

United Therapeutics Corp. (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options with an exercise price of $117.76 per share and acquired 9,500 common shares on September 30, 2026. Family trusts sold 7,580 common shares that day; the exercise and sale of the resulting shares were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported stock-option position after the exercise was 328,410 shares.

United Therapeutics Corporation (UTHR) Chairperson & CEO Martine A. Rothblatt reported that stock options held in a family trust were exercised for 9,500 common shares at an exercise price of $117.76 per share on September 29, 2026; 9,500 trust-held common shares were sold that day in multiple transactions.

The exercise and sales were pursuant to a pre-arranged 10b5-1 trading plan Rothblatt adopted on November 7, 2025. The plan will continue until the earlier of exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026.

A family trust in which United Therapeutics Chairperson & CEO Martine A. Rothblatt shares investment power exercised 9,500 stock options on September 28, 2026, at an exercise price of $117.76 per share, then sold the resulting 9,500 common shares in 14 transactions. Reported weighted-average sale prices ranged from $472.4274 to $486.0050 per share. The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shares investment power exercised 9,500 stock options on September 25, 2026, at $117.76 per share and received 9,500 common shares. The trust sold those shares that day in multiple transactions: 40 shares at $470.5565; 200 at $471.8378; 800 at $472.8860; 543 at $474.1472; 1,613 at $475.2775; 2,744 at $476.1324; 1,280 at $477.1915; 1,648 at $478.1807; and 632 at $478.9522 per share. Each reported sale price is a weighted average. The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

A family trust associated with United Therapeutics Corp. Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options on September 24, 2026, at an exercise price of $117.76, followed by sales of the resulting 9,500 common shares. Reported sale prices ranged from $469.7352 to $480.3300 per share. The exercise and sales were made under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported option position following the exercise was 366,410 options.

Martine A. Rothblatt, United Therapeutics Corp.'s Chairperson & CEO, reported that family trusts in which she shares investment power exercised 9,500 stock options on September 23, 2026, at an exercise price of $117.76 per share, then sold 9,500 resulting common shares. The reported stock-option position following the exercise was 375,910.

The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The plan will continue until the earlier of exercise of 1,734,410 stock options, all expiring March 15, 2027, or December 31, 2026.

A family trust in which United Therapeutics (UTHR) Chairperson & CEO Martine Rothblatt shares investment power exercised options for 9,500 common shares at an exercise price of $117.7600 on September 22, 2026; the reported option position afterward was 385,410. The resulting shares were sold through family trusts in ten transactions that day: 240 at $489.6121, 424 at $490.5378, 736 at $491.4469, 628 at $492.6678, 1,645 at $493.7018, 1,337 at $494.6585, 1,488 at $495.7662, 1,484 at $496.8295, 1,358 at $497.7257 and 160 at $499.0681 per share. Each reported sale price was a weighted average. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine Rothblatt, through family trusts, exercised stock options for 9,500 shares of common stock at an exercise price of $117.76 per share on September 21, 2026, and sold all 9,500 resulting shares at weighted-average prices between about $492.97 and $496.62 per share. The option exercise and related sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025, and the trusts continued to hold 394,910 stock options after the transaction.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options on September 18, 2026 at an exercise price of $117.76 per share, receiving 9,500 shares of common stock. On the same date, those 9,500 shares were sold in multiple open-market transactions at weighted average prices generally between the $492–$498 range. Following the option exercise, family trusts associated with Rothblatt held 404,410 stock options, and she also held 40,513 common shares directly and 166 shares indirectly through her spouse. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock of UNITED THERAPEUTICS at an exercise price of $117.76 per share on September 17, 2026, and the resulting 9,500 common shares were sold in a series of trades between roughly $492.71 and $501.70 per share. Following the option exercise, the reporting person's family trust held 413,910 stock options that expire on March 15, 2027. The option exercise and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which remains in effect until the earlier of the exercise of 1,734,410 options expiring March 15, 2027, or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) reported that executive vice president and general counsel Paul A. Mahon exercised employee stock options and sold the resulting shares on September 17, 2026. He exercised 8,300 stock options$146.03

On the same date, he sold 8,300 shares$496–$50247,540 stock optionsRule 10b5-1 trading plan

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options for common stock on September 16, 2026 at an exercise price of $117.76 per share, receiving 9,500 shares indirectly.

On the same date, the family trust sold 9,500 shares of common stock in multiple transactions at prices ranging from $497.69 to $505.26 per share. These trades were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026. After the option exercise, a family trust associated with the reporting person held 423,410 stock options with the same March 15, 2027 expiration.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options on September 15, 2026 at an exercise price of $117.76 per share and acquired an equal number of common shares. The trusts then sold 9,500 common shares in multiple open-market transactions at weighted average prices around $500–$505 per share, all pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, family trusts report holding 432,910 stock options from the same grant, while Rothblatt also reports 40,513 UTHR shares held directly and 166 shares held indirectly by spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $117.76 per share on September 14, 2026, receiving 9,500 common shares and then selling those 9,500 shares in multiple open-market trades around $502–$506 per share. The option exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, and 442,410 options of this grant remain held by a family trust after the exercise.

UNITED THERAPEUTICS Corp (UTHR) director Nilda Mesa exercised stock options for 130 shares of common stock on September 14, 2026 at an exercise price of $110.86 per share, then sold a total of 228 shares in two transactions at prices around $505.8 per share. Following the option exercise, she held 6,430 stock options directly, and no transactions were reported under a Rule 10b5-1 trading plan.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options for common stock at $117.76 per share and on September 11, 2026 sold 9,500 common shares in multiple trades at prices around $497–$508 per share. After the exercise, the trust held 451,910 stock options, while separate holding entries show 40,513 shares held directly and 166 shares held indirectly by spouse. The option exercise and related sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 10, 2026, and sold the resulting 9,500 common shares in multiple trades around $498–$509 per share.

The option exercise and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025. After the exercise, a family trust held 461,410 stock options expiring March 15, 2027, and Rothblatt also reported 40,513 common shares held directly and 166 shares held indirectly by spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 9, 2026, and the resulting 9,500 shares were sold in multiple open-market transactions at prices generally around $494–$509 per share.

The option exercise was from a grant expiring March 15, 2027, leaving 470,910 options held indirectly by a trust after the transaction. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Rothblatt also reports 40,513 shares held directly and 166 shares held indirectly by a spouse, in addition to other trust holdings.

UNITED THERAPEUTICS Corp (UTHR) reports that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 8, 2026, and the trust sold 9,500 common shares in multiple trades on the same date.

The filing states these transactions were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, and that 480,410 stock options expiring March 15, 2027 remain held indirectly by a family trust after this exercise.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine Rothblatt, through a family trust, exercised 9,500 stock options on September 4, 2026 at an exercise price of $117.76 per share and received 9,500 shares of common stock. The trust then sold 9,500 common shares the same day in multiple open-market transactions at weighted average prices between roughly $485 and $492 per share under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. Following the option exercise, the family trust continues to hold 489,910 stock options expiring March 15, 2027, and Rothblatt also has 40,513 common shares held directly and 166 shares held indirectly by a spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised stock options for 9,500 shares of common stock on September 3, 2026, at strike prices of $135.42 and $117.76 per share and sold 9,500 shares in multiple trades at prices ranging from about $478.44 to $491.55. These transactions were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Following these transactions, Rothblatt is reported as holding 40,513 shares directly and 166 shares indirectly through a spouse, with additional holdings and options in family trusts where she and/or her spouse share investment power.

UNITED THERAPEUTICS Corp (UTHR) executive Paul A. Mahon, EVP & General Counsel, reported exercising stock options for 8,300 shares of common stock on September 3, 2026 at an exercise price of $146.03 per share and selling the resulting 8,300 shares in a series of trades on the same date. The filing states these option exercises and share sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. Following the exercise, Mahon continues to hold 55,840 stock options directly.

UNITED THERAPEUTICS Corp (UTHR) disclosed that family trusts associated with Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share on September 2, 2026, acquiring 9,500 common shares indirectly and selling 9,500 common shares in multiple transactions around $478–$510 per share.

The option exercise and related sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After this exercise, the relevant family trust held 8,910 stock options, while Rothblatt also held 40,513 common shares directly and 166 shares indirectly through a spouse.

For UNITED THERAPEUTICS Corp (UTHR), Chairperson & CEO Martine A. Rothblatt reported an exercise of 9,500 stock options at an exercise price of $135.42 per share on September 1, 2026, held indirectly through a family trust. The options converted into 9,500 shares of common stock, which were then sold indirectly by the trust in a series of open-market transactions totaling 9,500 shares at weighted average prices ranging from about $510.43 to $516.57 per share. After the option exercise, the trust reported holding 18,410 stock options of the same series. The filing also lists 40,513 shares of common stock held directly, and 166 shares held indirectly by a spouse. All option exercises and related sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring March 15, 2027, or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) reports that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock on August 31, 2026. The same day, those 9,500 shares were sold in multiple trades at weighted average prices around $508–$515 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After this option exercise, a family trust holds 27,910 stock options, while Rothblatt also reports 40,513 shares of common stock held directly and 166 shares held indirectly by spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised stock options for 9,500 shares of common stock at an exercise price of $135.42 per share on August 28, 2026. The resulting 9,500 shares of common stock were then sold in multiple open-market transactions at weighted-average prices generally between about $514 and $524 per share, each trade executed in multiple lots within specified price ranges. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which contemplates the potential exercise of up to 1,734,410 stock options expiring March 15, 2027, or earlier termination on December 31, 2026. Following these transactions, reported holdings include 40,513 shares of common stock held directly, 166 shares held indirectly by a spouse, and 37,410 stock options held in a family trust, with additional shares and options held through various family trusts where the reporting person and immediate family members are beneficiaries.